186 related articles for article (PubMed ID: 33826999)
1. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
Meng GQ; Wang JS; Wang YN; Wei N; Wang Z
Int Immunopharmacol; 2021 Jul; 96():107606. PubMed ID: 33826999
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
[TBL] [Abstract][Full Text] [Related]
3. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report.
Zhu M; Zhang J; Shi Q; Sun X; Wang H; Sun M; Liu Y
Iran J Immunol; 2023 Dec; 20(4):466-472. PubMed ID: 37873944
[TBL] [Abstract][Full Text] [Related]
4. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.
Shamriz O; Kumar D; Shim J; Briones M; Quarmyne MO; Chonat S; Lucas L; Edington H; White MH; Mahajan A; Park S; Chandrakasan S
J Clin Immunol; 2021 Oct; 41(7):1582-1596. PubMed ID: 34173902
[TBL] [Abstract][Full Text] [Related]
5. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Virology and Immune Inflammation of Epstein-Barr Virus Infection Related Non-Neoplastic Diseases in Children.
Wang Q; Duan Z; Duan W; Ruan M; Zhang Y; Zhang H; Zhou Q
Clin Lab; 2024 May; 70(5):. PubMed ID: 38747912
[TBL] [Abstract][Full Text] [Related]
7. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
[TBL] [Abstract][Full Text] [Related]
8. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus (EBV)-induced B-cell Lymphoproliferative Disorder Mimicking the Recurrence of EBV-associated Hemophagocytic Lymphohistiocytosis.
Yatsushiro Y; Nishikawa T; Saito A; Nakazawa Y; Imadome KI; Nakagawa S; Kodama Y; Okamoto Y; Kanegane H; Kawano Y
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e44-e46. PubMed ID: 29324572
[TBL] [Abstract][Full Text] [Related]
10. Resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis associated with rapid immune reconstruction after a single course of CHOP therapy.
Chikagawa Y; Hikishima K; Mizumaki H; Sugimori C; Nakagishi Y; Yachie A; Nakao S
Int J Hematol; 2020 Dec; 112(6):889-893. PubMed ID: 32725606
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis.
Toga A; Wada T; Sakakibara Y; Mase S; Araki R; Tone Y; Toma T; Kurokawa T; Yanagisawa R; Tamura K; Nishida N; Taneichi H; Kanegane H; Yachie A
J Infect Dis; 2010 Jun; 201(12):1923-32. PubMed ID: 20443735
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease.
Jin Z; Wang Y; Wei N; Wang Z
Ann Hematol; 2020 Jul; 99(7):1575-1581. PubMed ID: 32500223
[TBL] [Abstract][Full Text] [Related]
13. Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.
Stefanou C; Tzortzi C; Georgiou F; Timiliotou C
BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 27941111
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group.
Kogawa K; Sato H; Asano T; Ohga S; Kudo K; Morimoto A; Ohta S; Wakiguchi H; Kanegane H; Oda M; Ishii E
Pediatr Blood Cancer; 2014 Jul; 61(7):1257-62. PubMed ID: 24535916
[TBL] [Abstract][Full Text] [Related]
15. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
Yao S; He L; Zhang R; Liu M; Hua Z; Zou H; Wang Z; Wang Y
Ann Med; 2023 Dec; 55(1):89-100. PubMed ID: 36533966
[TBL] [Abstract][Full Text] [Related]
16. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
Papageorgiou SG; Tsiodras S; Siakallis G; Bazani E; Spathis A; Poulakou G; Korkolopoulou P; Panayiotides I; Pappa V
Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
[TBL] [Abstract][Full Text] [Related]
18. Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy.
Tejedor I; Tedbirt B; Carvalho P; Duval-Modeste AB; Joly P; Hébert V
Melanoma Res; 2022 Dec; 32(6):485-487. PubMed ID: 36125885
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features and outcome analysis of 83 childhood Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-2004 protocol].
Xiao L; Xian Y; Dai BT; Su YC; Xiao JW; Zheng QC; Zhao XD; Yu J
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):668-72. PubMed ID: 22339824
[TBL] [Abstract][Full Text] [Related]
20. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
Balamuth NJ; Nichols KE; Paessler M; Teachey DT
J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
